NASDAQ: CYCCP - Cyclacel Pharmaceuticals, Inc.

Rentabilité sur six mois: -31.24%
Rendement en dividendes: +2.99%
Secteur: Healthcare

Calendrier des promotions Cyclacel Pharmaceuticals, Inc.


À propos de l'entreprise Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.

plus de détails
It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

IPO date 2005-11-30
ISIN US23254L2079
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 2.99
Дивиденд ао 0.6
Сайт https://www.cyclacel.com
Цена ао 18.2
Changement de prix par jour: 0% (6.47)
Changement de prix par semaine: +6.94% (6.05)
Changement de prix par mois: -4.15% (6.75)
Changement de prix sur 3 mois: -7.57% (7)
Changement de prix sur six mois: -31.24% (9.41)
Changement de prix par an: -60.36% (16.32)
Evolution du prix sur 3 ans: -19.13% (8.0001)
Evolution du prix sur 5 ans: +1 152.18% (0.5167)
Evolution des prix sur 10 ans: 0% (6.47)
Evolution des prix depuis le début de l'année: -13.73% (7.5)

Sous-estimation

Nom Signification Grade
P/S 34.42 1
P/BV 23.81 1
P/E 0 0
EV/EBITDA -0.3672 0
Total: 3.5

Efficacité

Nom Signification Grade
ROA, % -256.16 0
ROE, % -3715.82 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 2.99 7.48
DSI 0.8571 8.57
Total: 5.15

Devoir

Nom Signification Grade
Debt/EBITDA -0.0012 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -50.18 0
Rentabilité Ebitda, % 159.41 10
Rentabilité EPS, % 5522790.8 10
Total: 7.6

Établissements Volume Partager, %
Sound Income Strategies, LLC 182 14.46
UBS Group AG 17 1.35



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Spiro George Rombotis President, CEO & Executive Director 612.47k 1959 (66 années)
Mr. Paul McBarron Executive VP of Finance, CFO, COO, Secretary & Executive Director 321.61k 1961 (64 année)
Ms. Gill Christie Director of Human Resources N/A 1957 (68 années)
Dr. Brian Schwartz M.D. Chief Medical Officer & Director 53k 1962 (63 année)
Grace Kim Investor Relations Executive N/A

Adresse: United States, Berkeley Heights. NJ, 200 Connell Drive - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.cyclacel.com